Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc)

(Synonyms: tumor necrosis factor (ligand) superfamily, member 11, TRANCE, TNFSF11, sOdf, RANKL, OPTB2, OPGL, ODF, hRANKL2, CD254) Copy Product Info

Synonyms: tumor necrosis factor (ligand) superfamily, member 11, TRANCE, TNFSF11, sOdf, RANKL, OPTB2, OPGL, ODF, hRANKL2, CD254

Catalog No. TMPY-03674 Copy Product Info
Purity: 97.5%
RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with mFc tag. The predicted molecular weight is 52.4 kDa and the accession number is AAC51762.1.

Batch Information

Select Batch
Purity:97.5%
Appearance:Lyophilized powder
Color:White
Contact us for more batch information

Product Introduction

Bioactivity
Bioactivity
1.Measured by its binding ability in a functional ELISA. Immobilized Human TNFRSF11B His at 2 μg/ml (100 μl/well) can bind Human RANKL mFc, the EC50 of Human RANKL mFc is 15-80 ng/mL. 2. The bioactivity of hRANKL was determined by measuring the ability of hRANKL to induce TRAP activity in Raw 264.7 cells. The ED50 for this effect is typically 15-45 ng/mL.
Description
RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with mFc tag. The predicted molecular weight is 52.4 kDa and the accession number is AAC51762.1.
Species
Human
Expression System
HEK293 Cells
TagN-mFc
Accession NumberAAC51762.1
ConstructionA DNA sequence encoding the human TNFSF11 (AAC51762.1) (Gly63-Asp244) was expressed with the Fc region of mouse IgG1 at the N-terminus. Predicted N terminal: Asp
Protein Purity
> 90 % as determined by SDS-PAGE
RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc)
Endotoxin< 1.0 EU/μg of the protein as determined by the LAL method.
FormulationLyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
ReconstitutionReconstituted with sterile deionized water to 0.25 mg/mL. Reconstitution conditions may vary depending on the lot.
Synonymstumor necrosis factor (ligand) superfamily, member 11, TRANCE, TNFSF11, sOdf, RANKL, OPTB2, OPGL, ODF, hRANKL2, CD254
Research Background
Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein that belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
Chemical Properties
Molecular Weight52.4 kDa (predicted); 50-60 kDa (reducing condition, due to glycosylation)
Storage & Solubility Information
ShippingIn general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
StorageIt is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Calculator

  • Reconstitution Calculator
  • Recombinant Protein Dilution Calculator
  • Specific Activity Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Keywords

Related Tags: RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc) chemical structure | RANKL/TNFSF11/CD254 Protein, Human, Recombinant (mFc) molecular weight